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Abstract
Objective To determine whether lower cerebral blood flow
(CBF) is associated with faster cognitive decline in patients
with Alzheimer’s disease (AD).
Methods We included 88 patients with dementia due to AD
from the Amsterdam Dementia Cohort. Mean follow-up was
2±1 years. Linear mixed models were used to determine as-
sociations of lower whole brain and regional pseudo-
continuous arterial spin labelling measured CBF with rate of
cognitive decline as measured with repeated mini-mental state
examination (MMSE). Model 1 was adjusted for age, sex, and
education. Model 2 was additionally adjusted for normalized
gray matter volume, medial temporal lobe atrophy, white mat-
ter hyperintensities, microbleeds, and lacunes. Analyses were
repeated after partial volume correction (PVC) of CBF.
Statistical significance was set at p≤0.05.
Results Patients were 65±7 years old, 44 (50 %) were wom-
en, and mean baseline MMSE was 22±4. Annual decline
(β[SE]) on the MMSE was estimated at -2.11 (0.25) points
per year. Lower whole brain (β[SE]-0.50[0.25]; p≤0.05) and
parietal (β[SE]-0.59[0.25]; p<0.05) CBF were associated
with faster cognitive decline. PVC cortical CBF was not as-
sociated with cognitive decline.
Conclusions Lower CBF, in particular in the posterior brain
regions, may have value as a prognostic marker for rate of
cognitive decline in AD.
Key points
• In AD, lower CBF is associated with more rapid cognitive
decline.
• Decreasing CBF does not reach a plateau early in AD.
• PcASL-CFB has additive value to conventional structural
MRI measures in AD.
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Abbreviations and acronyms
MMSE Mini-mental state examination
MTA Medial temporal lobe atrophy
PCASL Pseudo-continuous arterial spin-labelling
PRCPCC Precuneus and posterior cingulate cortex
PVC Partial volume corrected
WMH White matter hyperintensities
Introduction
Alzheimer’s disease (AD) is a progressive neurodegenerative
disorder and one of the aspects that determines progression is
cognitive decline. In AD, cognitive decline appears to be large-
ly variable between individual patients [1, 2] and predictors of
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cognitive decline in patients with dementia due to AD are cur-
rently largely lacking [3]. Moreover, with the introduction of
new research criteria for preclinical AD [4], the focus of re-
search is shifting more and more towards prognostic factors
in the early, or preclinical, phase of AD [5]. Factors that predict
decline in early phases of the disease, however, may lack prog-
nostic value once patients are diagnosed with dementia [6].
Cerebral blood flow (CBF) may be a relevant prognostic
factor for the rate of cognitive decline in patients with AD.
CBF can be measured with arterial spin labelling (ASL) and is
found to be lower in AD patients compared to controls [7–9].
Decreased CBF is thought to reflect synaptic failure [10–12].
Synaptic dysfunction continues throughout the course of AD
[13] and is still associated with cognitive decline in later stages
of AD [14]. Lower ASL-CBF has been found to predict con-
version from mild cognitive impairment (MCI) to AD [15].
Moreover, a lower ASL-CBF has been associated with worse
cognition, even in the stage of AD dementia [8]. Using single-
photon emission computed tomography (SPECT), fast declin-
ing AD patients also appeared to have a lower baseline CBF
than more slowly declining patients [16, 17].
Several previous reports show that ASL-CBF is able to
predict progression in healthy controls and MCI patients
[15, 18]. At present it is unknown whether ASL-CBF also
has prognostic value for the rate of disease progression in
patients with dementia due to AD. We aimed to investi-
gate whether CBF measured with ASL is associated with
the rate of cognitive decline in patients with AD.
Methods
Patients
From the Amsterdam Dementia Cohort [19], we selected all
AD patients who underwent a pseudo-continuous ASL
(pcASL) MRI scan during 2010-2012 (n=178, Fig. 1). We
excluded patients with structural brain lesions (n=5: two with
post-traumatic lesions; two with brain tumour; one with a large
recent haemorrhage) and patients for whom pre-processing of
the ASL MRI data failed (n=10); this resulted in a potential
dataset of 163 AD patients with available ASL. Of these, 88
patients met our inclusion criterion of at least two MMSE
scores available over at least 1 year of follow-up. Excluded
patients had on average a lower MMSE score (19±5 vs. 22
±4, p<0.01), but both groups were comparable with regard to
demographics and MRI characteristics (data not shown).
Standardized work-up included a physical and neuro-
logic examination, extensive neuropsychological testing,
laboratory tests, and brain magnetic resonance imaging
(MRI). All results were discussed in a multidisciplinary
meeting, after which the diagnosis “probable AD” was
made according to the NINCDS-ADRDA criteria [20],
and all patients fulfilled the core clinical criteria of the
NIA-AA [21] (more details on this standardized work-up
can be found in van der Flier et al [19]). For all patients
we had information about education, classified using the
Verhage scale [22].
The medical ethics committee of the VUUniversityMedical
Center approved the study. All patients provided written in-
formed consent to use their clinical data for research purposes.
MRI acquisition
MRI scans were performed on a 3 T whole body MR system
(SignaHDxt, GE Medical Systems Milwaukee, WI, USA)
using an 8-channel head coil. The scan protocol included
T1-weighted, T2-weighted, fluid-attenuated inversion recov-
ery (FLAIR), and gradient echo T2*-weighted images.Medial
temporal lobe atrophy (MTA) was rated on the oblique recon-
structions of the T1-weighted images, using a 5-point rating
scale (0-4) [23]. For analyses we used the mean of left and
right MTA scores. White matter hyperintensities (WMH)
were assessed using the Fazekas scale on the FLAIR im-
ages, with scores from 0 to 3 [24]. Microbleeds were
defined as small round foci of hypointense signal, up to
10 mm in brain parenchyma on T2*-weighted images.
Lacunes were defined as deep lesions (3-15 mm) with
CSF-like signal on all sequences. Microbleeds and
lacunes were counted. The rater was blinded to the pa-
tients’ clinical data.
PcASL [25, 26] perfusion images (3D-FSE acquisition
with background suppression, post-label delay 2.0 s, echo
time = 9 ms, repetition time = 4.8 s, spiral readout 8 arms x
512 samples; 36 × 5.0 mm axial slices, 3.2 × 3.2 mm in-
plane resolution, reconstructed pixel size 1.7 × 1.7 mm,
acquisition time 4 min) were calculated using a single
compartment model [27] after the subtraction of labeled
Fig. 1 Flow chart of patient inclusion
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from control images. CBF was described by using the
following equation:
CBF ¼ λ 1−e−TSAT
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with post-label delay w=2.0 s, labelling time τ=1.5 s, parti-
tion coefficient λ=0.9, labelling efficiency ε=0.8*0.75 (label
PCASL * background suppression), T1 of blood T1B=1.4 s,
SR time for PD image TSAT=2.0 s, and correction for SR in
PD image T1GM=1.2 s. ΔS stands for ASL difference image
and S0 for proton density-weighted reference image.
Post-processing of MRI data
Both T1-weighted and pcASL images were corrected for
gradient non-linearities in all three directions. Further
data analyses were carried out using FSL (version 4.1;
http://www.fmrib.ox.ac.uk/fsl). Processing of T1 images
consisted of non-brain tissue removal [28], linear regis-
tration to standard space [29] and tissue segmentation
[30] yielding partial volume estimates. These steps are
conveniently combined in FSL Sienax, which addition-
ally produces a normalized gray matter volume (NGMV)
with reference to the MNI standard brain. CBF maps
[31] were linearly registered to the brain-extracted T1
images. Partial volume estimates were transformed to
the ASL data space and used in a regression algorithm
[32], using a 3D Gaussian kernel of 9.5 mm full width at
half maximum, to create a partial volume corrected
(PVC) cortical CBF map. Partial volume estimates were
subsequently used as a weighting factor to calculate
corrected cortical CBF. The MNI152 atlas and the
Harvard-Oxford cortical atlas (both part of FSL) were
used to create regions-of-interest (ROIs) of the frontal,
parietal, precuneus, and posterior cingulate cortex
(PRCPCC), temporal and occipital brain areas, to extract
mean uncorrected and PVC CBF values for each region.
Additionally, the uncorrected mean whole brain CBF
was calculated as the average perfusion of all voxels
classified as brain tissue, including CSF.
Cognitive follow-up
Follow-up took place by clinical routine visits to our memory
clinic. All patients had at least one follow-up, no less than
1 year after baseline. At follow-up the MMSE was used as a
measure of general cognitive function [33].
Data analysis
We used SPPS version 20 (for Windows) for the statistical
analyses. Linear mixed models were applied to assess the
associations for whole brain and regional CBF (frontal, pari-
etal, PRCPCC, temporal, and occipital) with rate of decline on
the MMSE. A linear mixed model has increased statistical
power as it accounts for within-person correlations over time,
allows different numbers of assessments and accounts for
varying time intervals between assessments. CBF was
analysed per standard deviation decrease (SD), as a step of
1 mL/100 g/min may be too small to be informative. All
MMSE assessments, including those at baseline were taken
into account. A random intercept and random slope with time
(in years) were assumed, meaning that the model accounted
for individual variation of change in MMSE over time.
The model included terms for the CBF measurement,
time, the interaction between CBF and time (all as inde-
pendent factors), and covariates. The dependent variable
consisted of all MMSE scores. Model 1 was adjusted for
age, sex, and education. In model 2, we additionally ad-
justed for NGMV, MTA, WMH, microbleeds, and
lacunes. Next, we repeated these analyses (without adjust-
ment for NGMV in model 2) using PVC cortical CBF.
Statistical significance was set at p< 0.05.
Results
Table 1 presents the demographics, MRI characteristics, and
CBF measurements of the patients in the study. Patients had a
mean age of 65±7 years and 44 (50%)were women. Baseline
MMSE was 22±4, and average follow-up was 2±1 years.
The total number of MMSE tests that were included in the
analyses was 277. Median number of MMSE tests within one
patient was three, with a minimum of two and a maximum of
eight. Annual change (β[SE]) in MMSE was estimated at -
2.11(0.25) points per year.
As expected, whole brain CBF was lower than PVC corti-
cal CBF, as the former also contains cerebrospinal fluid and
white matter.
Table 2 shows results of the linear mixed models we
used to investigate the associations between baseline CBF
with baseline MMSE and with annual change in MMSE.
CBF measures were not associated with MMSE at base-
line. Adjusted for age, sex, and education (model 1), low-
er whole brain CBF was associated with faster decline on
the MMSE (β[SE]: -0.50[0.25], p= 0.05). When looking
at region specific CBF, we found that in particular lower
parietal CBF was associated with a more rapid cognitive
decline. Lower occipital CBF tended to be associated with
more rapid cognitive decline, although this association did
not reach significance (p= 0.06). CBF in the other regions
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was not associated with cognitive decline. When we per-
formed additional adjustments for structural MRI mea-
sures (model 2), the associations remained largely
comparable.
Whole brain PVC cortical CBF was not associated with
annual decline on the MMSE (model 1: β[SE] -0.39
[0.25], n.s.). In addition, we found no associations be-
tween regional PVC cortical CBF and annual decline on
the MMSE (data not shown).
Discussion
We found that a lower CBF in patients with AD was associ-
ated with faster cognitive decline over a mean follow-up pe-
riod of 2 years. This effect was strongest for lower parietal
CBF and this association was independent of structural MRI
measures for neurodegeneration and small vessel disease.
The major finding of this study is that CBF was indepen-
dently associated with cognitive decline in patients with AD.
This is a novel finding that seems in line with previous papers
[15, 18] that report that a lower ASL-CBF predicts progres-
sion in cognitively healthy elderly and MCI patients. In addi-
tion, two studies using SPECT report a lower baseline CBF in
faster declining AD patients compared with slowly declining
patients [16, 17]. We found that a lower parietal CBF showed
the strongest association with subsequent cognitive decline. A
lower CBF in AD patients has been found to be most pro-
nounced in posterior regions [7, 9, 31]. Moreover, the finding
that lower CBF in these regions is associated with decline is in
line with previous studies [16–18]. Several lines of research
highlight the relevance of posterior brain regions in AD.
EEG abnormalities have, for instance, been found to be
most severe in the posterior regions [34] and atrophy in
these regions has also been associated with more rapid
disease progression in AD [35]. Overall, our findings in-
dicate that posterior CBF can provide relevant informa-
tion regarding disease progression in AD.
Contrary to our expectation, we found no cross-sectional
association between a lower CBF and a lower score on the
MMSE. Possibly the current patient selection (patients with
available follow-up) may account for the discrepancy with our
previous work [8, 31], as the selected patients had a slightly
higher baseline MMSE. Moreover, we found no associations
for PVC cortical CBF with cognitive decline and we feel
currently not able to explain why the associations were differ-
ent for uncorrected and PVC cortical CBF. Partial volume
effects related to cerebral atrophy may hamper CBF measure-
ment [32]. However, the association for whole brain and pa-
rietal CBF remained significant after adjustment for NGMV
and MTA. Whereas this may seem contradictory at first sight,
we also like to point out that among the many different
methods that currently exist to apply PVC, there is still no
perfect or gold standard [36]. By looking at uncorrected
CBF we remain the closest to our original data and this seems,
therefore, most useful for extrapolation to a clinical setting, as
no additional processing is necessary.
Whereas absolute CBF values may vary across studies
as a result of perfusion measurement techniques, a con-
sistent finding is lower CBF values in AD patients com-
pared to controls [7, 37]. Changes in CBF are generally
tightly linked to changes in brain glucose metabolism,
and a decrease in CBF is thought to reflect synaptic
failure [10–12]. Synapse loss is assumed to be the most
Table 1 Patient demographics
n = 88
Age (years) 65 ± 7
Female sex a 44 (50 %)
Follow-up time (years) 2 ± 1
Level of education (Verhage scale) 5 ± 1
Baseline MMSE score 22± 4
Median number of MMSEsb 3 (2 - 8)
Annual change in MMSE c -2.11 ± 0.25
MRI characteristics
Normalized gray matter volume (ml) 715.8 ± 44.6
Medial temporal lobe atrophyb, d 1.5 (0-3)
White matter hyperintensitiesb, e 1 (0-3)
Microbleedsb 0 (0-100)
Lacunesb 0 (0-2)
Cerebral blood flow (mL/100 g/min)
Whole brain 28.0 ± 5.6
PVC cortical 43.0 ± 8.7
Regional cerebral blood flow (mL/100 g/min)
Frontal 18.7 ± 4.7
Parietal 23.9 ± 5.9
PRCPCC 30.2 ± 6.8
Temporal 21.8 ± 5.1
Occipital 29.1 ± 7.7
Regional PVC cerebral blood flow (mL/100 g/min)
Frontal 43.2 ± 10.0
Parietal 47.3 ± 10.9
PRCPCC 53.8 ± 11.8
Temporal 39.0 ± 8.3
Occipital 48.7 ± 10.7
Availability for incomplete data: Level of education 87/88; Microbleeds
86/88
Data are represented as mean± standard deviation, patients with variable
present (%)a or median (range) b .
c Calculated with linear mixed models, to make use of all available
MMSE values. Given value is the unadjusted main effect of time.
Key: MMSE, mini-mental state examination; PVC, partial volume
corrected.
d Medial temporal lobe atrophy was rated with a visual rating scale (0-4).
e White matter hyperintensities were rated with the Fazekas scale (0-3).
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direct pathological substrate of cognitive decline in AD [38],
and abnormalities in synaptic functioning are also assumed to
cause network disturbance [39]. Connectivity research shows
that highly active areas, among which the posterior regions,
are in particular affected in AD [40]. The association that we
found between decreased posterior CBF and cognitive decline
may, therefore, reflect network disruption. Nevertheless, de-
creased CBF may also reflect the presence of vascular disease
[9]. A considerable part of AD patients has concomitant cere-
bral amyloid angiopathy (CAA) [41]. Interestingly, cerebro-
vascular amyloid deposition is found to be largest in posterior
brain regions. The importance of decreased posterior CBF for
cognitive decline may, therefore, also be associated with the
presence of CAA. Overall, we found, however, that the asso-
ciations of a lower parietal and occipital CBF with cognitive
decline were independent of MRI markers for neurodegener-
ation and small vessel disease.
A strength of our study is the availability of longitudinal
cognitive data in a well-characterized set of AD patients.
Another strength is the use of linear mixed models for the
statistical analyses. These models allow patients to have
variable numbers of follow-up assessment as they take
into account that the estimate of cognitive decline is less
precise when patients have fewer follow-up measure-
ments. In addition, we used 3D pcASL with whole-brain
coverage to study CBF. A major advantage for use in a
memory clinic population is that ASL can be performed
during the same scanning session as structural images.
A possible limitation is that we included a purely clinical
sample. All included patients were asked to return to the out-
patient clinic not solely for research purposes, but also as a
part of the clinical routine. This might have induced a selec-
tion bias, as only patients for whom follow-up was thought to
be relevant were invited for follow-up and could be included
in the present study. Indeed we found that patients included in
the present study had a slightly higher baselineMMSE, but we
found no differences in any of the other characteristics. Since
invitations for follow-up were made blinded to CBF values,
this selection will not have confounded our results. A limita-
tion with regard to the ASL is that, ideally multiple post-label
delay times would be used to account for delayed transit times,
as excessively long arrival times may result in regional under-
estimation of CBF. Nevertheless, the delay time of 2.0 s that
we used is recommended for a memory clinic population and
is assumed to limit the impact of variation in transit time on
the measured CBF [25]. In addition, it is known that caffeine
intake and medication use may influence CBF and hence ASL
measurement. We did not correct for any of these effects.
Moreover, using the MMSE as a measure for cognitive de-
cline might be considered a limitation as well, as this is a
rather crude measure of cognition. Nonetheless, the MMSE
is a generally widely accepted test for the evaluation of
Table 2 Cerebral blood flow and cognitive decline
Model 1 Model 2
Estimated Baseline
MMSE
Estimated annual change inMMSE Estimated Baseline
MMSE
Estimated annual change inMMSE
Whole brain CBF a -0.42 ± 0.38 -0.50 ± 0.25* -0.10 ± 0.40 -0.50 ± 0.25*
Regional CBF a
Frontal -0.16 ± 0.41 -0.13 ± 0.26 0.29± 0.43 -0.13 ± 0.26
Parietal -0.63 ± 0.38 -0.59 ± 0.25** -0.22 ± 0.44 -0.59 ± 0.25**
PRCPCC -0.60± 0.38. -0.41 ± 0.25 -0.17 ± 0.42 -0.43 ± 0.25
Temporal -0.31 ± 0.37 -0.46 ± 0.25 -0.10 ± 0.41 -0.45 ± 0.25
Occipital -0.39 ± 0.37 -0.47 ± 0.25¥ -0.05 ± 0.40 -0.46 ± 0.25¥
Data are represented asβ± SE. Linear mixed models were used to investigate associations between CBF and change inMMSE. A random intercept and
random slope for time (in years) were assumed. The model includes terms for the CBFmeasure, time, the interaction between the CBFmeasure and time
and covariates. The βs for estimated baseline MMSE represent the estimated additional change in z-score associated with a standard deviation decrease
in CBF at baseline. The βs for estimated annual change in MMSE represent estimated additional change in z-score for each year of follow-up.
Abbreviations: MMSE, mini-mental state examination; CBF, cerebral blood flow.
Model 1: adjusted for age, sex, and education.
Model 2: additional adjustment for normalized gray matter volume, medial temporal lobe atrophy, white matter hyperintensities, microbleeds, and
lacunes.
** p = 0.02
* p = 0.05
¥ p= 0.06
a CBFwas inverted (i.e. higher is worse) and given per standard deviation increase (worsening). Negativeβs indicate that a worse CBF is associatedwith
a decline in MMSE.
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cognition in elderly patients and is easy to obtain, thus maxi-
mizing the number of patients with available data.
Previous studies showed that CBF starts to decrease early
in the process of AD and that CBF decreases precede struc-
tural brain volume changes [8, 42]. Our current results seem-
ingly fit with the notion that decreasing CBF, similar to other
measures of synaptic failure [13, 14] or network dysfunction
[43], does not reach a plateau early in the disease, but is asso-
ciated with ongoing cognitive decline once patients are diag-
nosed with dementia due to AD. ASL scans are relatively easy
to obtain and can be acquired during the same scanning ses-
sion as structural MRI images and they may, therefore, be a
promising additional tool. Whereas the associations that we
found between lower CBF and faster cognitive decline were
found in group-level analyses, perfusion measured with ASL
may have prognostic value in individual patients as well. We
found that the use of classifiers that predict diagnoses based on
single-subject ASL are promising (Collij LE, Heeman F,
Kuijer JP et al: Application of machine learning to arterial
spin labelling in mild cognitive impairment and Alzheimer's
disease. Radiology 2016; accepted). Possibly we will be able
to develop classifiers that use perfusion MRI to predict cog-
nitive decline. Overall, our results indicate that pcASL-CFB
may have additive value to the conventional structural MRI
measures: AD patients with a lower posterior CBF at the time
of diagnosis show a more rapid cognitive decline.
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